To test for the role of PRG-1/PP2A signaling in mediating PRG-1-dependent bone cancer induced pain, we preformed hippocampal microinjection of FTY720 (D39-43, 20 μg once per day), which serves as an activator of PP2A 76 and PRG-1/PP2A signaling 35, and BCP rats showed a significant increase in TWL and MWT with cumulative effect (Figure 4E-G) and also rescued sucrose preference of BCP rats (Figure 4H). Here, PLPPR4 is linked to bone cancer.